- Home
- NAGE vs MNMD Comparison
NAGE vs MNMD Comparison
Compare NAGE & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAGE
- MNMD
- Stock Information
- Founded
- NAGE 1999
- MNMD 2019
- Country
- NAGE United States
- MNMD United States
- Employees
- NAGE N/A
- MNMD N/A
- Industry
- NAGE Medicinal Chemicals and Botanical Products
- MNMD Pharmaceuticals and Biotechnology
- Sector
- NAGE Health Care
- MNMD Health Care
- Exchange
- NAGE Nasdaq
- MNMD Nasdaq
- Market Cap
- NAGE 861.0M
- MNMD 709.9M
- IPO Year
- NAGE N/A
- MNMD N/A
- Fundamental
- Price
- NAGE $9.82
- MNMD $9.37
- Analyst Decision
- NAGE Strong Buy
- MNMD Strong Buy
- Analyst Count
- NAGE 3
- MNMD 7
- Target Price
- NAGE $17.00
- MNMD $24.71
- AVG Volume (30 Days)
- NAGE 803.7K
- MNMD 1.1M
- Earning Date
- NAGE 10-30-2025
- MNMD 11-06-2025
- Dividend Yield
- NAGE N/A
- MNMD N/A
- EPS Growth
- NAGE N/A
- MNMD N/A
- EPS
- NAGE 0.22
- MNMD N/A
- Revenue
- NAGE $116,303,000.00
- MNMD N/A
- Revenue This Year
- NAGE $28.46
- MNMD N/A
- Revenue Next Year
- NAGE $21.65
- MNMD N/A
- P/E Ratio
- NAGE $44.84
- MNMD N/A
- Revenue Growth
- NAGE 35.90
- MNMD N/A
- 52 Week Low
- NAGE $3.16
- MNMD $4.70
- 52 Week High
- NAGE $14.69
- MNMD $11.02
- Technical
- Relative Strength Index (RSI)
- NAGE 50.03
- MNMD 50.26
- Support Level
- NAGE $9.16
- MNMD $8.70
- Resistance Level
- NAGE $9.77
- MNMD $9.95
- Average True Range (ATR)
- NAGE 0.38
- MNMD 0.56
- MACD
- NAGE 0.03
- MNMD -0.04
- Stochastic Oscillator
- NAGE 59.88
- MNMD 31.90
About NAGE Niagen Bioscience Inc. Common Stock
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).